Johnson & Johnson trials show single-shot COVID-19 vaccine effective


Johnson & Johnson's coronavirus vaccine proved safe and provoked an immune response in young and elderly volunteers alike, according to trial results published Wednesday in the New England Journal of Medicine. Most trial participants got just one shot of a high or low vaccine dose, or a placebo, although some people aged 18 to 55 got two doses. Most of the volunteers who got the vaccine produced the neutralizing antibodies, which defend cells from the virus, after 28 days. Researchers reported some side effects, including fever, fatigue, headache, and pain at the injection site. Dr. Paul Stoffels, chief scientific officer at J&J, said the data gave the company "confidence" the vaccine will prove highly effective. Results from the larger phase-three trial are expected later this month.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.
-
The US-China trade war comes to Hollywood
Under the Radar China's retaliatory restrictions on foreign films will hurt the US film industry
By Genevieve Bates
-
Ione Skye's 6 favorite books about love and loss
Feature The actress recommends works by James Baldwin, Nora Ephron, and more
By The Week US
-
Book review: 'Miracles and Wonder: The Historical Mystery of Jesus' and 'When the Going Was Good: An Editor's Adventures During the Last Golden Age of Magazines'
Feature The college dropout who ruled the magazine era and the mysteries surrounding Jesus Christ
By The Week US
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
By Peter Weber, The Week US
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
By Peter Weber, The Week US
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
By Peter Weber, The Week US
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US